Chromatin remodeling factor CHD5 is silenced by promoter CpG island hypermethylation in human cancer

Epigenetics

Volumn 3, Issue 4, 2008, Pages 210-215

  Mulero Navarro, Sonia ^a,b   Esteller, Manel ^a,c  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b Centro Nacional de Investigaciones Oncológicas   (Spain)

^c INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

Chromatin remodeling; Chromodomain; CpG island; DNA methylation; Human cancer

Indexed keywords

ADENOSINE TRIPHOSPHATE; CHROMODOMAIN HELICASE DNA BINDING PROTEIN; DNA BINDING PROTEIN; HELICASE; MESSENGER RNA; UNCLASSIFIED DRUG;

ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN STRUCTURE; CHROMOSOME ABERRATION; COLON CARCINOMA; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DNA RECOMBINATION; DNA REPAIR; GENE CONTROL; GENE INACTIVATION; GENE REPLICATION; GENE SILENCING; GENETIC TRANSCRIPTION; GENOME; GLIOMA; HUMAN; HUMAN CELL; NEOPLASM; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FAMILY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 54949152670     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.3.4.6610     Document Type: Article

References (18)

1. Weber M, Davies JJ, Wittig D, Oakeley EJ, Haase M, Lam WL, Schubeler D. Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet 2005; 37:853-62.
2. Costello JF, Fruhwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, Wright FA, Feramisco JD, Peltomaki P, Lang JC, Schuller DE, Yu L, Bloomfield CD, Caligiuri MA, Yates A, Nishikawa R, Su Huang H, Petrelii NJ, Zhang X, O'Dorisio MS, Held WA, Cavenee WK, Plass C. Aberrant CpG-island methylation has non-random and tumor-type-specific patterns. Nat Genet 2000; 24:132-8.
3. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001; 61:3225-9.
4. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE. The consensus coding sequences of human breast and colorectal cancers. Science 2006; 314:268-74.
5. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, Bonaldi T, Haydon C, Ropero S, Petrie K, Iyer NG, Perez-Rosado A, Calvo E, Lopez JA, Cano A, Calasanz MJ, Colomer D, Piris MA, Ahn N, Imhof A, Caldas C, Jenuwein T, Esteller M. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005; 37:391-400.
6. Eisen JA, Sweder KS, Hanawalt PC. Evolution of the SNF2 family of proteins: subfamilies with distinct sequences and functions. Nucleic Acids Res 1995; 23:2715-23.
7. Flanagan JF, Mi LZ, Chruszcz M, Cymborowski M, Clines KL, Kim Y, Minor W, Rastinejad F, Khorasanizadeh S. Double chromodomains cooperate to recognize the methylated histone H3 tail. Nature 2005; 438:1181-5.
8. Sims RJ, 3rd, Chen CF, Santos-Rosa H, Kouzarides T, Patel SS, Reinberg D. Human but not yeast CHD1 binds directly and selectively to histone H3 methylated at lysine 4 via its tandem chromodomains. J Biol Chem 2005; 280:41789-92.
9. Bello MJ, Leone PE, Nebreda P, de Campos JM, Kusak ME, Vaquero J, Sarasa JL, Garcia-Miguel P, Queizan A, Hernandez-Moneo JL, et al. Allelic status of chromosome 1 in neoplasms of the nervous system. Cancer Genet Cytogenet 1995; 83:160-4.
10. Bieche I, Champeme MH, Matifas F, Cropp CS, Callahan R, Lidereau R. Two distinct regions involved in 1p deletion in human primary breast cancer. Cancer Res 1993; 53:1990-4.
11. Praml C, Finke LH, Herfarth C, Schlag P, Schwab M, Amler L. Deletion mapping defines different regions in 1p34.2-pter that may harbor genetic information related to human colorectal cancer. Oncogene 1995; 11:1357-62.
12. Thompson PM, Gotoh T, Kok M, White PS, Brodeuar GM. CHD5, a new member of the chromodomain gene family, is preferentially expressed in the nervous system. Oncogene 2003; 22:1002-11.
13. Bagchi A, Papazoglu C, Wu Y, Capurso D, Brodt M, Francis D, Bredel M, Vogel H, Mills AA. CHD5 is a tumor suppressor at human 1p36. Cell 2007; 128:459-75.
14. Marfella CG, Imbalzano AN. The Chd family of chromatin remodelers. Mutat Ret 2007; 618:30-40.
15. de la Serna IL, Ohkawa Y, Imbalzano AN. Chromatin remodeling in mammalian differentiation: lessons from ATP-dependent remodellers. Nat Rev Genet 2006; 7:461-73.
16. Vissers LE, van Ravenswaaij CM, Admiraal R, Hurst JA, de Vries BB, Janssen IM, van der Vliet WA, Huys EH, de Jong PJ, Hamel BC, Schoenmakers EF, Brunner HG, Veltman JA, van Kessel AG. Mutations in a new member of the chromodomain gene family cause CHARGE syndrome. Nat Genet 2004; 36:955-7.
17. Law ME, Templeton KL, Kirange G, Smith J, Misra A, Feuerstein BG, Jenkins RB. Molecular cytogenetic analysis of chromosomes 1 and 19 in glioma cell lines. Cancer Genet Cytogenet 2005; 160:1-14.
18. Fujita T, Igarashi J, Okawa ER, Gotoh T, Manne J, Kolla V, Kim J, Zhao H, Pawel BR, London WB, Maris JM, White PS, Brodeur GM. CHD5, a tumor suppressor gene deleted front 1p36.31 in neuroblastomas. J Natl Cancer Inst 2008; 2:940-9.